Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Sage Therapeutics	Hutchison China MediTech	I-Mab	Reata Pharmaceuticals	FibroGen
Symbol	NASDAQ:SAGE	NASDAQ:HCM	NASDAQ:IMAB	NASDAQ:RETA	NASDAQ:FGEN
Price Information
Current Price	$72.92	$29.31	$55.63	$90.85	$20.32
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.4	1.4	1.4	1.4	1.8
Analysis Score	3.3	3.5	3.5	3.5	4.1
Community Score	3.1	2.7	3.3	2.6	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.8	1.7
Earnings & Valuation Score	0.6	0.6	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$86.69	$40.00	$70.00	$237.43	$45.83
% Upside from Price Target	18.88% upside	36.47% upside	25.83% upside	161.34% upside	125.56% upside
Trade Information
Market Cap	$4.29 billion	$4.22 billion	$4.09 billion	$3.23 billion	$1.87 billion
Beta	2.23	1.12	N/A	1.57	1.59
Average Volume	493,373	233,153	359,016	287,748	1,490,590
Sales & Book Value
Annual Revenue	$6.87 million	$204.89 million	$4.31 million	$26.52 million	$256.58 million
Price / Sales	619.68	20.83	928.63	124.01	7.29
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$18.23 per share	$2.35 per share	$3.34 per share	$7.74 per share	$6.14 per share
Price / Book	4.00	12.47	16.66	11.74	3.31
Profitability
Net Income	$-680,240,000.00	$-106,020,000.00	$-208,560,000.00	$-290,170,000.00	$-76,970,000.00
EPS	($13.38)	($0.80)	($28.90)	($9.54)	($0.89)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-7,706.84%	N/A	N/A	-4,340.72%	-191.78%
Return on Equity (ROE)	-63.81%	N/A	N/A	-163.42%	-48.19%
Return on Assets (ROA)	-56.64%	N/A	N/A	-56.49%	-27.72%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.07%	N/A	N/A	N/A
Current Ratio	11.71%	3.14%	N/A	12.98%	6.23%
Quick Ratio	11.71%	3.01%	N/A	12.98%	6.13%
Ownership Information
Institutional Ownership Percentage	N/A	33.45%	16.64%	64.30%	75.05%
Insider Ownership Percentage	4.80%	N/A	N/A	31.70%	3.39%
Miscellaneous
Employees	298	1,280	185	261	599
Shares Outstanding	58.38 million	145.62 million	71.95 million	36.20 million	92.07 million
Next Earnings Date	5/4/2021 (Confirmed)	N/A	N/A	5/10/2021 (Estimated)	5/6/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, DOX and FGEN finance.yahoo.com - April 21 at 12:03 AM
	Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Yahoo Finance finance.yahoo.com - April 20 at 7:02 PM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action - GlobeNewswire globenewswire.com - April 20 at 7:02 PM
	FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed - Yahoo Finance finance.yahoo.com - April 20 at 7:02 PM
	Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. finance.yahoo.com - April 20 at 7:02 PM
	FibroGen (NASDAQ:FGEN) Shares Up 5.3% americanbankingnews.com - April 20 at 1:40 PM
	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Business Wire businesswire.com - April 20 at 8:55 AM
	FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders finance.yahoo.com - April 20 at 8:55 AM
	Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN - Yahoo Finance finance.yahoo.com - April 19 at 10:22 PM
	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo Finance finance.yahoo.com - April 19 at 10:22 PM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - Yahoo Finance finance.yahoo.com - April 19 at 10:22 PM
	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN finance.yahoo.com - April 19 at 10:22 PM
	Lawsuit filed for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN) - openPR openpr.com - April 19 at 5:22 PM
	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Yahoo Finance finance.yahoo.com - April 19 at 5:22 PM
	Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit - The Reporter thereporteronline.com - April 19 at 5:22 PM
	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) finance.yahoo.com - April 19 at 5:22 PM
	INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm finance.yahoo.com - April 19 at 5:22 PM
	Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit finance.yahoo.com - April 19 at 5:22 PM
	FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders finance.yahoo.com - April 19 at 5:22 PM
	Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN finance.yahoo.com - April 19 at 5:22 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo Finance finance.yahoo.com - April 19 at 12:22 PM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - KPVI News 6 kpvi.com - April 19 at 12:22 PM
	FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire businesswire.com - April 19 at 12:22 PM
	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established finance.yahoo.com - April 19 at 12:22 PM
	FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm finance.yahoo.com - April 19 at 12:22 PM
	FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co. marketbeat.com - April 7 at 10:12 AM
	FibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of America marketbeat.com - March 31 at 7:42 AM

Date	Company	Brokerage	Action
4/19/2021	Sage Therapeutics	Morgan Stanley	Lower Price Target
4/12/2021	Sage Therapeutics	Mizuho	Reiterated Rating
4/7/2021	Sage Therapeutics	Piper Sandler	Initiated Coverage
3/3/2021	Sage Therapeutics	Oppenheimer	Boost Price Target
2/25/2021	Sage Therapeutics	HC Wainwright	Boost Price Target
2/1/2021	Sage Therapeutics	Raymond James	Initiated Coverage
1/22/2021	Sage Therapeutics	BMO Capital Markets	Downgrade
1/19/2021	Sage Therapeutics	Wedbush	Boost Price Target
1/4/2021	Sage Therapeutics	Guggenheim	Upgrade
1/4/2021	Sage Therapeutics	Royal Bank of Canada	Downgrade
12/4/2020	Sage Therapeutics	William Blair	Reiterated Rating
12/1/2020	Sage Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
12/1/2020	Sage Therapeutics	Truist	Boost Price Target
12/1/2020	Sage Therapeutics	Smith Barney Citigroup	Lower Price Target
10/2/2020	Hutchison China MediTech	Deutsche Bank Aktiengesellschaft	Initiated Coverage
3/12/2020	Hutchison China MediTech	Cantor Fitzgerald	Initiated Coverage
2/20/2020	Hutchison China MediTech	The Goldman Sachs Group	Initiated Coverage
11/19/2019	Hutchison China MediTech	CLSA	Initiated Coverage
10/23/2019	Hutchison China MediTech	Bank of America	Initiated Coverage
7/5/2019	Hutchison China MediTech	Macquarie	Initiated Coverage
3/27/2019	Hutchison China MediTech	HSBC	Initiated Coverage
3/22/2021	I-Mab	Needham & Company LLC	Initiated Coverage
2/13/2020	I-Mab	CICC Research	Initiated Coverage
2/12/2020	I-Mab	China Renaissance Securities	Initiated Coverage
2/11/2020	I-Mab	Jefferies Financial Group	Initiated Coverage
8/10/2020	Reata Pharmaceuticals	Stifel Nicolaus	Lower Price Target
6/16/2020	Reata Pharmaceuticals	BTIG Research	Initiated Coverage
6/12/2020	Reata Pharmaceuticals	Robert W. Baird	Reiterated Rating
11/13/2019	Reata Pharmaceuticals	National Securities	Downgrade
4/13/2021	FibroGen	JPMorgan Chase & Co.	Upgrade
4/13/2021	FibroGen	SVB Leerink	Lower Price Target
5/1/2020	FibroGen	Cowen	Initiated Coverage

(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources